Table 2.
Best symptom and functionality response while receiving GXR, by psychiatric comorbidities of interest (post-hoc analyses)
| Comorbidity (MedDRA preferred term) | Improvement, n (%)a | ||
|---|---|---|---|
| ADHD symptom assessmentb | Functionality assessmentb | ||
| School performance | Homelife | ||
| Oppositional defiant disorder, n = 92 | 64 (69.6) | 54 (58.7) | 51 (55.4) |
| Learning disability, n = 70 | 52 (74.3) | 51 (72.9) | 48 (68.6) |
| Anxiety, n = 53 | 39 (73.6) | 38 (71.7) | 36 (67.9) |
| Autism spectrum disorder, n = 35 | 24 (68.6) | 24 (68.6) | 21 (60.0) |
ADHD attention-deficit/hyperactivity disorder, GXR guanfacine extended-release, MedDRA Medical Dictionary for Regulatory Activities
aPercentages were calculated using the number of patients in the respective comorbidity categories as denominator
bGeneral physician assessment